Clinical trial
A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin)…
NCT02132949 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT02132949 |
|---|---|
| Title | A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer |
| Official title | A Multicenter, Multinational, Phase II Study to Evaluate Perjeta in Combination With Herceptin and Standard Neoadjuvant Anthracycline-Based Chemotherapy in Patients With HER2-Positive, Locally Advanced, Inflammatory, or Early-Stage Breast Cancer |
| Acronym | BERENICE |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab |
| Enrollment | 401 |
| Start date | Jul 14, 2014 |
| Primary completion | Mar 3, 2016 |
| Completion | Aug 25, 2020 |
| First posted | May 7, 2014 |
| Last update posted | Sep 17, 2021 |
| Countries | Canada, Denmark, France, Germany, Italy, Mexico, Norway, Poland, Portugal, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: